============================================= 2nd Annual Neurodegenerative Disorders 2005 16th - 17th February Marriott Kensington, London ============================================= **** CONFERENCE BROCHURE AVAILABLE NOW - REQUEST YOURS TODAY **** 2nd Annual Neurodegenerative Disorders 2005 will explore the current unmet needs and highlight opportunities in the market by pinpointing potential therapeutic targets. In this conference, pioneering experts will share their concepts and current findings in novel therapeutic targets and treatments, to expose new pathways into drug developments. In addition, experts from pharmaceutical organization will demonstrate methods to maximize your R&D profit by strategic marketing and building cooperative platform to accelerate drug launches. THEMES WILL INCLUDE: **Profit from emerging trends in ND therapeutics **New approaches to improve clinical development for your organization **Learn from the best practice case studies such as: Aventis, Wyeth, Eli Lilly and Roche **Examine areas shaping the future of ND therapies: disease modification, proteomic, phamacogenetics and stem cell therapies **Pinpoint where opportunities lie: explore alliances and collaborations **Advancements in medical technologies **Streamline product launches by integrating business strategies in R&D KEY SPEAKERS **Dr. Steve Offord, Head, New Products CNS/Thrombosis, Global Marketing & Medical, Aventis **Dr. Menelas Pangalos, Vice President, Neuroscience Research, Wyeth **Dr. Christian Czech, Senior Research Scientist, CNS Research, Pharmaceutical Division, Roche **Dr. Michel Dib, Medical Director for CNS Department, Aventis **Dr. Michael O'Neill, Team & Project Leader, Discovery Neuroscience, Eli Lilly **Dr. Brian Dickie, Director, Research, Motor Neuron Disease Association **Dr. David Burn, Consultant Neurologist & Reader in Movement Disorder Neurology, Newcastle General Hospital **Dr. Ana Martinez, Director, R&D, Neuropharma **Dr. Jette Bisgaard Boll, Department of Molecular Disease Biology, Lundbeck **Dr. Karoly Nikolich, Founder & Chief Scientific Officer, AGY Therapeutics **Dr. Johan Häggblad, Head, Business Development, NeuroNova **Dr. Grant Krafft, Chairman & Chief Scientific Officer, Acumen Pharmaceuticals ------------------ WHO SHOULD ATTEND ------------------ **Director, CNS Clinical Discovery & Human Pharmacology **Director, R&D **Project Leader, Neurology Project Management Group **Vice President, Drug Development **Chief Scientific Officer **Chief Operating Officer **Clinical Pharmacologist **Managing Director **General Counsel **Medical Director, Internal Medicines **Medical Manager --------------------- DELEGATE REGISTRATION --------------------- Places at this event are strictly limited so BOOK YOUR PLACE NOW. To make a booking on this event, please contact me via phone or email. Book early to secure a place. - PRICING - Attend the: 2 Day conference - ONLY GBP1299 plus VAT - BOOKINGS - Booking is easy, simply contact me: Joe Stone Account Manager - Conference Division Visiongain B2B Conferences Tel. +44(0)20 8767 6711 Fax. +44(0)20 8767 5001 mailto:joe.stone@visiongain.com www.b2b-conferences.com B2B Conferences is part of the Visiongain Group **** FULL CONFERENCE AGENDA BELOW **** ======================================================================= PRE-CONFERENCE INTERACTIVE WORKSHOP Tuesday 15th February 2005 Strategies for Pricing and Market Access of New Neurodegenerative Drugs Led by: Ulf Munack, Director, Simon-Kucher & Partners ======================================================================= Workshop schedule This workshop will give you the opportunity to engage in knowledge-sharing with fellow professionals, which can result in brainstorming and creating ideas which you can use back in your own organisation. You can gain a greater understanding of the pricing of neurodegenerative disorder drugs, have detailed discussions about market access and new ventures. It is of most use to those who are willing and prepared to engage in meaningful discussions and network with others. This 'facilitated open-space' provides you with ideas and time to explore possible new tideas and benchmark them against other approaches. Main topics of discussion: . P&R environment for NDs products in 2005 . Critical success factors for market access in neurodegenerative disorder . Examples of recent learning from new ND drug launches . What it means for R&D ==================================== Day One Wednesday 16th February 2005 ==================================== Conference Chair Day One Dr. Michel Dib Medical Director, CNS Aventis 09:00 Registration and coffee 09:30 Opening remarks from the chair GLOBAL MARKET TRENDS IN NEURODEGENERATIVE DISORDERS 09:40 Focusing on Clinical NDs Drug Development . What are the methodological issues in NDs clinical R&D? - Human models, proof of concept & time of intervention . Biomarkers in ND: from the diagnosis to the therapy - What we can do? Methods to effectively utilise biomarkers . What is the development plan for a new drug in the NDs? . Can we speak about one neurodegenerative process in all these diseases? - Lessons from the past, consequences for the future Dr. Michel Dib Medical Director, CNS Aventis 10:20 CASE STUDY: Glutamate Mechanisms - Promising Therapeutic Target? . Glutamate receptor subtypes: Review of biology & pharmacology - What have we learnt so far? . How to use glutamate pathways to search for effective neuroprotection? . Examine efficaious results of in vitro neuroprotective studies . How to modulate glutamate to develop novel therapies? . Explore NMDA, AMPA and mGlu receptors: Examples of in vivo neuroprotection . Evaluate current clinical data of neuroprotective properties Dr. Michael O'Neill Team & Project Leader, Discovery Neuroscience Eli Lilly 11:00 Coffee 11:20 CASE STUDY: Novel Insights & Therapeutic Opportunities . Human CNS disease - A global health concern . Conceptual & technical approaches towards novel therapies - Genomics and proteomics: how effective are they? . Analyse AGY's approaches to CNS R&D development - Focus on mechanistic pathways: Genomics & proteomics . Explore novel mechanistic pathway involved in NDs . Understand the underlying cause of the diseases . Future outlook of NDs R&D: Pinpoint where opportunities lie Dr. Karoly Nikolich Founder & Chief Scientific Officer AGY Therapeutics 12:00 CASE STUDY: Targeting Stem Cell Therapies . Focus on the underlying cause of neurodegeneration . How to develop compounds to target stem cells? . "Therapeutic Neurogenesis" - analyse the mechanism of action . Examine clinical evidence of efficacious results . Explore potential candidates - possible collaboration? . The future prospects of stem cell therapies' clinical application? - Discover where opportunities lie within stem cell therapies - How can the technology be implemented into your R&D? Dr. Johan Häggblad Head, Business Development NeuroNova 12:40 Lunch 14:00 Integrating Business Strategies into NDs R&D . Methods to develop common mechanism platforms . Cross-functional team - Enhance communication between departments i.e. marketing vs scientists - Feasibility, regulatory risks, unmet needs and market value . How to shorten time of profit vacuum? - Create commercial strategies at early stage - Optimize scientific creativity . Understanding the value of NDs drugs Dr. Steve Offord Head, New Products CNS/Thrombosis, Global Marketing & Medical Aventis ADVANCES IN THE TREATMENT OF PARKINSON'S DISEASE 14:40 Understanding PD Unmet Needs . R&D advancements through the years:What have we learnt so far? . Designing novel PD therapies - Multifactorial considerations - Motor and non-motor complications . Examine potential therapeutic targets . Promising compounds in the pipeline - Clinical evidence, trial data and safety assessment . What do we hope for in the future Dr. David Burn Consultant Neurologist & Reader in Movement Disorder Neurology Newcastle General Hospital 15:20 Afternoon Tea 15:40 CASE STUDY: Collaborated Approach to Novel Therapy . Identify current problematic issues faced by physicians - Transplantation of embryonic nigral tissues - Poor survival of dopaminergic neurones . CEP-1347 - mixed-lineage-kinase (MLK) inhibitor: Discover mechanism of action and efficacious results . The future of the compound - A collaborated effort . The pros and cons of collaborated approaches - What to watch for and ideas to resolve problematic issues Dr. Jette Bisgaard Boll Department of Molecular Disease Biology Lundbeck 16:20 CASE STUDY: Advancements in Medical Technologies . Symptomatic relief: dyskinetic movements . Implantation procedures and mechanism of action . Current success stories in surgical interventions - Activa and N'Vision Programmer . Areas of improvement: Where partnerships can be formed . Positive clinical results of mid-brain stimulation on other symptoms:Pinpoint areas of combination therapies Dr. Abed Hammoud Procedure Solution Manager, Neurological Medtronic NOVEL THERAPEUTIC TARGETS IN ALZHEIMER'S DISEASE 17:00 CASE STUDY: Anti-ADDL Therapeutics: Reversing Synaptic Degeneration and LTP Deficits . ADDLs, NOT fibrils, cause AD and MCI . Evidence: ADDLs attack specific synapses to compromise LTP . ADDL intervention strategies - treatment and prevention . Explore anti-ADDL antibody therapeutics - What can you learn? - Discovery of ADDL assembly blockers and receptor antagonists . What are the future outlook of Anti-ADDL therapeutics? Dr. Grant Krafft Chairman and Chief Scientific Officer Acumen Pharmaceuticals 17:40 Question and Discussion 18:00 Summation of Day One from Chairman =================================== Day Two Thursday 17th February 2005 =================================== Conference Chair Day Two Dr. Menelas Pangalos Vice President, Neuroscience Research Wyeth 09:00 Registration and coffee 09:30 Opening remarks from the chair 09:40 CASE STUDY: Challenges in CNS Drug Discovery . Why is CNS drug discovery so important? . Anaylse NDs prevalence statistics and unmet needs . Problematic issues with long-winding drug discovery process . Wyeth's AD drug discovery programmes - Explore novel therapeutic targets - How to expand R&D pipeline? . Focus on advancement in clinical approaches and trends in collaboration - What can you implement? Dr. Menelas Pangalos Vice President, Neuroscience Research Wyeth 10:20 CASE STUDY: New Disease Modifying Approaches in AD . Roche's approach to AD R&D -Disease modification therapies - Target amyloid and APP to delay disease progression - What can you implement in your pipeline? . Analyse current promising compounds in Roche's AD pipeline - Analyse efficacious clinical results and drug trials . Focus on cost effective therapies to optimize market needs - Novel methods to penetrate the market . Future outlook on AD's clinical studies - identifying global market trends Dr. Christian Czech Senior Research Scientist, CNS Research Pharmaceutical Division Roche 11:00 Morning Coffee 11:20 CASE STUDY: Neuropharma's Neuroprotective Project . Identify new neuroprotective agents and neuroprotective activity detection methods . Systematic search for neuronal antioxidants & calcium channel antagonists -Explore other new targets & candidates . Current pipeline analysis: NP031112 non atp-competitive GSK- 3ß enzyme inhibitor - Positive neuroprotectors . Neuropharma's future approaches in AD R&D and novel ideas on neuroprotective strategies Dr. Ana Martinez Director, R&D Neuropharma EMERGING TRENDS IN MOTOR NEURON DISEASE THERAPIES 12:00 Targeting Clinical R&D of Motor Neurone Disease . Overview of MNDs and the importance of treatments . Current clinical drug trials & explore promising compounds . Forecast of what will cause an impact on MNDs therapies - Examine mutant genes & protein aggregation in MND - Implement new therapeutic targets to penetrate MNDs market . What is HUGO and how will it impact MNDs R&D discoveries? . Identify current unmet needs & unmet needs in the market . How to improve overall treatments? Dr. Brian Dickie Director, Research Motor Neuron Disease Association 12:40 Lunch 14:00 CASE STUDY: Explore Emerging Options in Multiple Sclerosis Therapeutics . Overview - Aetiology, pathophysiology and unmet needs . The MS therapeutics pipeline - Multiple targeting strategies . Immunopathological hypothesis - Targeting CNS inflammation - Examine evidence of promising results . Discover neuroprotection approaches - Targeting axonal loss . BTG Ageing & Neuroscience's team focus on MS - Novel concepts and therapeutic targets . What is the future of MS therapies? Market trends and ways to predict answers to global unmet needs Dr. Russell Hagan Head, Ageing and Neuroscience BTG 14:40 CASE STUDY: Methods to Identify Biological Markers in CNS Development . Calpain inhibitors as "magic bullets" in the treatment of CNS disorders - Examine evidence of efficacious results . Discover the activation of calpain in neurodegeneration - Mechanism of action and therapeutic properties . Therapeutic approaches using calpain inhibitors in the treatment of DMD, MS, hearing loss and retinal degeneration - Methods to utilise calpain inhibitors in each treatment . Positive result on delaying degeneration of ALS Dr. Alfred Stracher Distinguished Professor & Chair / President & CEO State University of New York, CEPTOR Corp 15:20 Afternoon Tea EXPLORE NEW SCIENCE IN NEURODEGENERATIVE DISEASES 15:40 CASE STUDY: Promising New Drug - Miraxion . Etiology of Huntington's disease & global unmet needs . Miraxion - Therapeutic target and mechanism of action . Positive clinical trial results and recent multicentre studies data - Near term focus and targeted developmental approach . Estimated Miraxion global sales -How will it impact the market? . Opportunities in terms of market space and development? . What to expect in the coming years? Amarin's future approach and ideas in Huntington's R&D Rick Stewart CEO Amarin 16:20 CASE STUDY: Examine Possible Role of Chaperones in Protein Aggregation . Overview of Prion disease: Global prevalence & unmet needs - What have we learnt about Prion & aberrant proteins? . Current therapeutic treatments and targets in Prion R&D . Examine chaperone-facilitator: an RNA and non-nucleic acid serum component - Mechanism of action and efficacy studies . Possible therapeutic targets against Prion and other protein misfolding disease? Current evidence to show promising results Dr. Abraham Grossman Founder and Chief Scientific Officer Q-RNA 17:00 Questions and Discussion 17:20 Summation of Conference from chairman 17:30 Close of Conference Terms & Conditions NB - Due to high demand, we do not 'reserve' or 'hold' places - a request for an invoice to be raised will be treated as an official booking and will be subject to the cancellation policy as outlined below. Cancellations/substitutions and name changes: All bookings carry a 50% liability after the booking has been made, by post fax, email or web. There will be no refunds for cancellations received on or after one month before the start of the conference (e.g. cancellation on or after 20th January for a conference starting on 20th February). If you decide to cancel after this date the full invoice remains payable. Conference notes, which are available on the day, will be sent to you. Unfortunately we are not able to transfer places between conferences and executive briefings. However if you are unable to attend the event you may make a substitution/name change at any time as long as we are informed in writing by e-mail, fax or post. Name changes and substitutions must be from the same company and are not transferable between companies or countries. Indemnity: visiongain Ltd reserve the right to change the conference/executive briefing content, timing, speakers or venue without notice. The event may be postponed or cancelled due to acts of terrorism, war, extreme weather conditions, industrial action, acts of God or any event beyond the control of visiongain Ltd. If such a situation arises we will endeavour to reschedule the event. However, visiongain Ltd cannot be held responsible for any cost, damage or expenses, which may be incurred by the customer as a consequence of the event being postponed or cancelled. We therefore strongly advise all customers to take out insurance to cover the cost of the registration, travel and expenses. To unsubscribe please reply with unsubscribe in the subject line. Data protection: Visiongain Ltd gathers and manages data in accordance with the Data Protection Act 1998. Information contained about you may be used to update you on visiongain Ltd products and services via post, telephone, fax or email, unless you state otherwise. If you wish your details to be amended, please send your request to the Database Manager, visiongain Ltd, 40 Tooting High Street, London, SW17 0RG. Alternatively please reply with unsubscribe in the subject line. Please allow approximately 7 days for your removal or update request, you may receive additional pieces of communication from visiongain Ltd during the transitional period, whilst the changes come into effect. ************************************************************** Scanned by VisNetic MailScan for SMTP Servers. Visit http://www.deerfield.com/products/visnetic_mailscan. **************************************************************